课题基金 / 基金详情

STRUCTURE/FUNCTION HUMAN B CELL DIFFERENTIATION ANTIGENS

STRUCTURE/FUNCTION HUMAN B CELL DIFFERENTIATION ANTIGENS
结构/功能人 B 细胞分化抗原
批准号:
3293719
负责人:
Edward A Clark
金额:
$16.94万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1986
资助国家:
美国
项目状态:
已结题
起止时间:
1986-12-01 至 1994-12-31

项目摘要

项目成果

Edward A Clark的其他基金

相似基金

相关文献

中文摘要
翻译
这项计划的基本目标是研究人类B细胞 活化和生长通过细胞表面分子调节。 我们 将集中于表征配体和信号转导途径 通过三种主要的B细胞相关表面分子,即CD 20, CD 40和Bgp 95。 我们将使用一组激动性单克隆抗体, 这些标记物的抗体(mAb)和表达的全长cDNA 编码CD 20和CD 40的载体。 我们的具体目标是:目标1)定义 CD 20和CD 40的配体,利用用 CD 20或CD 40;目的2)表征信号转导 通过测量肌醇磷脂代谢, 目的3)分离编码Bgp 95的cDNA 用于表征该表面的结构和功能 参与调节B细胞活化的分子;和目的4) 评估膜蛋白酪氨酸磷酸酶(PTP 3) CD 45在调节能力(CD 20,Bgp 95)和进展(CD 40)中发挥作用 人类B细胞的信号。 这些研究不仅有助于阐明 调节小静息B细胞的基本机制,但也将 提供了新的信息,如何过渡的G 0到G1阶段的 细胞周期是可控的。
英文摘要
The fundamental goal of this proposal is to investigate how human B cell activation and growth are regulated through cell surface molecules. We will focus on characterizing the ligands and signal transduction pathways induced via three major B cell-associated surface molecules, namely CD20, CD40 and Bgp95. We will make use of a set of agonistic monoclonal antibodies (mAb) to these markers and full length cDNAs in expression vectors encoding CD20 and CD40. Our specific aims are: Aim 1) to define the ligands for CD20 and CD40, making use of cell lines transformed with either CD20 or CD40; Aim 2) to characterize the signal transduction pathways for CD20 and CD40 by measuring inositol phospholipid metabolism, protein kinases and/or anti-CD40; Aim 3) to isolate cDNAs encoding Bgp95 for use in characterizing the structure and function of this surface molecule involved in the regulation of B cell activation; and Aim 4) to assess the role that the membrane protein tyrosine phosphatase (PTPase) CD45 plays in regulating competence (CD20, Bgp95) and progression (CD40) signals in human B cells. These studies will help to elucidate not only the basic mechanisms regulating small resting B cells, but will also provide new information on how the transition of G0 to the Gl phase of the cell cycle is controlled.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of Novel CD180-Based Cancer Immunotherapeutics
  • 批准号:
    10381384
  • 项目类别:
  • 资助金额:
    $39.8万
  • 财政年份:
    2022
  • 负责人:
    Edward A Clark
  • 依托单位:
Mouse Resource Core
  • 批准号:
    8811087
  • 项目类别:
  • 资助金额:
    $36.75万
  • 财政年份:
    2015
  • 负责人:
    Edward A Clark
  • 依托单位:
Establishing and characterizing BAFF RFP reporter and BAFF knockin mice
  • 批准号:
    8468991
  • 项目类别:
  • 资助金额:
    $8.9万
  • 财政年份:
    2012
  • 负责人:
    Edward A Clark
  • 依托单位:
Establishing and characterizing BAFF RFP reporter and BAFF knockin mice
  • 批准号:
    8353277
  • 项目类别:
  • 资助金额:
    $8.9万
  • 财政年份:
    2012
  • 负责人:
    Edward A Clark
  • 依托单位:
海外基金